Pharmacokinetics of controlled-release oxycodone in patients with cancer pain

Kazuyo Nakamura, Hideya Kokubun, Toshiaki Komatsu, Motohiro Matoba, Sumio Hoka, Kazuo Yago

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Oxycodone is a useful analgesic for cancer patients in pain. However, its pharmacokinetics have not been sufficiently examined and there is a lack of information, with very few reports on pharmacokinetics concerning the absorption process in particular. With this in mind, we studied the pharmacokinetics of controlled-release oxycodone (Oxy contin). We measured its serum concentration in patients with cancer pain, and calculated parameters derived using the nonlinear least-squared method program (MULTI). In the result, pharmacokinetic parameters calculated at CL/F were: 45.6+/-22.0 L/hr (Mean+/-SD), Vd/F: 473.0+/-19 6.7 L, t(1/2): 7.2+/- 6.2 hr, kel: 0.103+/-0.034, kal: 1.082+/-0.604, Lag time: 0.9 9+/-0.40 hr. In addition, the serum oxycodone concentration hardly rose until 1 hour after and just before medication, whereupon a rapid increase was evident after 1 hour. The pharmacokinetics of controlled-release oxycodone in patients with cancer pain were clarified in this study. Especially during the absorption process, the lag time was calculated specifically at about 1 hour, making it approximately equal to MS contin.

Original languageEnglish
Pages (from-to)1449-1453
Number of pages5
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume34
Issue number9
Publication statusPublished - Jan 1 2007

Fingerprint

Oxycodone
Pharmacokinetics
Serum
Morphine
Analgesics
Cancer Pain
Pain
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Nakamura, K., Kokubun, H., Komatsu, T., Matoba, M., Hoka, S., & Yago, K. (2007). Pharmacokinetics of controlled-release oxycodone in patients with cancer pain. Gan to kagaku ryoho. Cancer & chemotherapy, 34(9), 1449-1453.

Pharmacokinetics of controlled-release oxycodone in patients with cancer pain. / Nakamura, Kazuyo; Kokubun, Hideya; Komatsu, Toshiaki; Matoba, Motohiro; Hoka, Sumio; Yago, Kazuo.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 34, No. 9, 01.01.2007, p. 1449-1453.

Research output: Contribution to journalArticle

Nakamura, K, Kokubun, H, Komatsu, T, Matoba, M, Hoka, S & Yago, K 2007, 'Pharmacokinetics of controlled-release oxycodone in patients with cancer pain', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 34, no. 9, pp. 1449-1453.
Nakamura K, Kokubun H, Komatsu T, Matoba M, Hoka S, Yago K. Pharmacokinetics of controlled-release oxycodone in patients with cancer pain. Gan to kagaku ryoho. Cancer & chemotherapy. 2007 Jan 1;34(9):1449-1453.
Nakamura, Kazuyo ; Kokubun, Hideya ; Komatsu, Toshiaki ; Matoba, Motohiro ; Hoka, Sumio ; Yago, Kazuo. / Pharmacokinetics of controlled-release oxycodone in patients with cancer pain. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2007 ; Vol. 34, No. 9. pp. 1449-1453.
@article{4353239a353f4dde83cbca6b8ebfbba2,
title = "Pharmacokinetics of controlled-release oxycodone in patients with cancer pain",
abstract = "Oxycodone is a useful analgesic for cancer patients in pain. However, its pharmacokinetics have not been sufficiently examined and there is a lack of information, with very few reports on pharmacokinetics concerning the absorption process in particular. With this in mind, we studied the pharmacokinetics of controlled-release oxycodone (Oxy contin). We measured its serum concentration in patients with cancer pain, and calculated parameters derived using the nonlinear least-squared method program (MULTI). In the result, pharmacokinetic parameters calculated at CL/F were: 45.6+/-22.0 L/hr (Mean+/-SD), Vd/F: 473.0+/-19 6.7 L, t(1/2): 7.2+/- 6.2 hr, kel: 0.103+/-0.034, kal: 1.082+/-0.604, Lag time: 0.9 9+/-0.40 hr. In addition, the serum oxycodone concentration hardly rose until 1 hour after and just before medication, whereupon a rapid increase was evident after 1 hour. The pharmacokinetics of controlled-release oxycodone in patients with cancer pain were clarified in this study. Especially during the absorption process, the lag time was calculated specifically at about 1 hour, making it approximately equal to MS contin.",
author = "Kazuyo Nakamura and Hideya Kokubun and Toshiaki Komatsu and Motohiro Matoba and Sumio Hoka and Kazuo Yago",
year = "2007",
month = "1",
day = "1",
language = "English",
volume = "34",
pages = "1449--1453",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "9",

}

TY - JOUR

T1 - Pharmacokinetics of controlled-release oxycodone in patients with cancer pain

AU - Nakamura, Kazuyo

AU - Kokubun, Hideya

AU - Komatsu, Toshiaki

AU - Matoba, Motohiro

AU - Hoka, Sumio

AU - Yago, Kazuo

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Oxycodone is a useful analgesic for cancer patients in pain. However, its pharmacokinetics have not been sufficiently examined and there is a lack of information, with very few reports on pharmacokinetics concerning the absorption process in particular. With this in mind, we studied the pharmacokinetics of controlled-release oxycodone (Oxy contin). We measured its serum concentration in patients with cancer pain, and calculated parameters derived using the nonlinear least-squared method program (MULTI). In the result, pharmacokinetic parameters calculated at CL/F were: 45.6+/-22.0 L/hr (Mean+/-SD), Vd/F: 473.0+/-19 6.7 L, t(1/2): 7.2+/- 6.2 hr, kel: 0.103+/-0.034, kal: 1.082+/-0.604, Lag time: 0.9 9+/-0.40 hr. In addition, the serum oxycodone concentration hardly rose until 1 hour after and just before medication, whereupon a rapid increase was evident after 1 hour. The pharmacokinetics of controlled-release oxycodone in patients with cancer pain were clarified in this study. Especially during the absorption process, the lag time was calculated specifically at about 1 hour, making it approximately equal to MS contin.

AB - Oxycodone is a useful analgesic for cancer patients in pain. However, its pharmacokinetics have not been sufficiently examined and there is a lack of information, with very few reports on pharmacokinetics concerning the absorption process in particular. With this in mind, we studied the pharmacokinetics of controlled-release oxycodone (Oxy contin). We measured its serum concentration in patients with cancer pain, and calculated parameters derived using the nonlinear least-squared method program (MULTI). In the result, pharmacokinetic parameters calculated at CL/F were: 45.6+/-22.0 L/hr (Mean+/-SD), Vd/F: 473.0+/-19 6.7 L, t(1/2): 7.2+/- 6.2 hr, kel: 0.103+/-0.034, kal: 1.082+/-0.604, Lag time: 0.9 9+/-0.40 hr. In addition, the serum oxycodone concentration hardly rose until 1 hour after and just before medication, whereupon a rapid increase was evident after 1 hour. The pharmacokinetics of controlled-release oxycodone in patients with cancer pain were clarified in this study. Especially during the absorption process, the lag time was calculated specifically at about 1 hour, making it approximately equal to MS contin.

UR - http://www.scopus.com/inward/record.url?scp=35348814235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348814235&partnerID=8YFLogxK

M3 - Article

C2 - 17876144

AN - SCOPUS:35348814235

VL - 34

SP - 1449

EP - 1453

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 9

ER -